AR079022A1 - Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion - Google Patents
Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacionInfo
- Publication number
- AR079022A1 AR079022A1 ARP100104007A AR079022A1 AR 079022 A1 AR079022 A1 AR 079022A1 AR P100104007 A ARP100104007 A AR P100104007A AR 079022 A1 AR079022 A1 AR 079022A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- series consisting
- ring
- chosen
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/54—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/50—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C307/04—Diamides of sulfuric acids
- C07C307/10—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/04—Seven-membered rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/02—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2
- C07D317/06—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2 condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/32—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D335/10—Dibenzothiopyrans; Hydrogenated dibenzothiopyrans
- C07D335/12—Thioxanthenes
- C07D335/14—Thioxanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D335/10—Dibenzothiopyrans; Hydrogenated dibenzothiopyrans
- C07D335/12—Thioxanthenes
- C07D335/14—Thioxanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
- C07D335/18—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/22—All rings being cycloaliphatic the ring system containing eight carbon atoms, e.g. pentalene
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/50—Spiro compounds
Abstract
Reivindicacion 1: Un compuesto de formula 1, en cualquiera de sus formas estereoisoméricas o una mezcla de formas estereoisoméricas en cualquier proporcion, o una sal farmacéuticamente aceptable del mismo, en la que el anillo A es un anillo monocíclico, bicíclico o espirocíclico de 3 miembros a 12 miembros, que comprende 0, 1 o 2 miembros hetero del anillo iguales o diferentes elegidos entre la serie que consiste en N, N(R0), O, S, S(O) y S(O)2, y que está saturado o comprende 1 doble enlace, con la condicion de que el anillo A no sea un anillo de biciclo[3.1.0]hexano o biciclo[3.2.0]heptano que tiene los grupos N(R20) y C(O)-R50 en su posicion 3, y no sea un anillo de octahidropentaleno, octahidroindeno o decahidroazuleno que tiene los grupos N(R20) y C(O)-R50 en su posicion 2, donde el anillo A está opcionalmente sustituido en los átomos de carbono del anillo con uno o más sustituyentes iguales o diferentes elegidos entre la serie que consiste en halogeno, R1, R2, alquenilo C2-6, HO-, R1-O-, fenil-alquil C1-4-O-, R1-C(O)-O-, R1S(O)2-O-, R1-S(O)m-, H2N-, R1-NH-, R1-N(R1)-, R1-C(O)-NH, R1-C(O)-N(R1)-, R1-S(O)2-NH-, R1-S(O)2-N(R1)-, R1-C(O)-, HO-C(O)-, R1-O-C(O)-, H2N-C(O)-, R1-NH-C(O)-, R1-N(R1)-C(O)-, H2N-S(O)2-, R1-NH-S(O)2-, R1-N(R1)-S(O)2-, F5S-, NC-, oxo y metileno; Y se selecciona entre la serie que consiste en N(R10), S, O, C(R12)=C(R13), N=C(R14) y C(R15)=N; Z se selecciona entre la serie que consiste en N y C(R16); R0 se selecciona entre la serie que consiste en hidrogeno y R1; R1 se elige entre la serie que consiste en alquilo C1-6, cicloalquilo C3-7 y cicloalquil C3-7-alquil C1-4-; R2 es alquilo C1-4 que está sustituido con uno o más sustituyentes iguales o diferentes elegidos entre la serie que consiste en HO- y alquil C1-4-O-; R10 se selecciona entre la serie que consiste en hidrogeno y R11; R11, R30, R33, R35, R54, R55, R57 y R58 son, independientemente entre sí, un grupo R11, R30, R33, R35, R54, R55, R57 y R58, elegidos entre la serie que consiste en alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7 y cicloalquil C3-7-alquil C1-4- que están todos opcionalmente sustituidos con uno o más sustituyentes R70 iguales o diferentes; R12, R13, R14, R15 y R16 se eligen, independientemente entre sí, entre la serie que consiste en hidrogeno, halogeno, alquilo , HO-alquil C1-4-, alquil C1-4-O-, alquil C1-4-S(O)m, H2N-, alquil C1-4-NH-, alquil C1-4-N(alquil C1-4)-, alquil C1-4-C(O)- y NC-, o R13 o R14, junto con uno de los grupos R21 y R22 que no es el grupo de la formula (2), forma una cadena que consiste en 3 a 5 miembros de cadena de los que 0, 1 o 2 miembros de cadena son miembros hetero de cadena iguales o diferentes elegidos entre la serie que consiste en N(R17), O y S, pero dos miembros hetero de cadena no pueden estar presentes en posiciones adyacentes, y los otros miembros de cadena son grupos C(R18)(R18) iguales o diferentes; R17 y R25 se seleccionan, independientemente uno del otro, de la serie que consiste en hidrogeno y alquilo C1-4; R18, independientemente de cualquier otro grupo R18, se elige entre la serie que consiste en hidrogeno, fluor y alquilo C1-4, o dos de los grupos R18 unidos al mismo átomo de carbono, junto con el átomo de carbono que los tiene, forma un anillo cicloalcano de 3 miembros a 6 miembros que está opcionalmente sustituido con uno o más sustituyentes iguales o diferentes elegidos entre la serie que consiste en fluor y alquilo C1-4; R20 se selecciona entre la serie que consiste en hidrogeno y alquilo C1-4; uno de los grupos R21 y R22 es un grupo de la formula (2) (R24-R23-) y el otro de los grupos R21 y R22 se elige entre la serie que consiste en hidrogeno, halogeno, R30, HO-, R30-O-, R30-C(O)-O-, R30-S(O)2-O-, R30-S(O)m, H2N-, R30-NH-, R30-N(R30)-, R30-C(O)-NH-, R30-C(O)-N(R71)-, R30-S(O)2-NH-, R30-S(O)2-N(R71)-, R30-C(O)-, HO-C(O)-, R30-O-C(O)-, H2N-C(O)-, R30-NH-C(O)-, R30-N(R30)-C(O)-, H2N-S(O)2-, R30-NH-S(O)2-, R30-N(R30)-S(O)2-, NC-, O2N- y Het1, o junto con R13 o R14 forma una cadena como se ha especificado en la definicion de R13 y R14; R23 es un enlace directo o una cadena que consiste en 1 a 5 miembros de cadena de los que 0, 1 o 2 miembros de cadena son miembros hetero de cadena iguales o diferentes elegidos entre la serie que consiste en N(R25), O, S, S(O) y S(O)2, pero dos miembros hetero de cadena pueden estar presentes en posiciones adyacentes solo si uno de ellos se elige entre la serie que consiste en S(O) y S(O)2 y el otro se elige entre la serie que consiste en N(R25), O y S, y los otros miembros de cadena son grupos C(R26)(R26) iguales o diferentes; R24 es un anillo monocíclico o bicíclico, de 3 miembros a 10 miembros, que está saturado y contiene 0 o 1 miembros hetero del anillo, o está insaturado y contiene 0, 1 o 2 miembros hetero del anillo iguales o diferentes, donde los miembros hetero del anillo se eligen entre la serie que consiste en N, N(R32), O, S, S(O) y S(O)2, y donde el anillo está opcionalmente sustituido en los átomos de carbono del anillo con uno o más sustituyentes iguales o diferentes elegidos entre la serie que consiste en halogeno, R33, oxetanilo, HO-, R33-O-, R33-C(O)-O-, R33-S(O)2-O-, R33-S(O)m-, H2N-, R33-NH-, R33-N(R33)-, R33-C(O)-NH-, R33-C(O)-N(R71)-, R33-S(O)2-NH-, R33-S(O)2-N(R71)-, H2N-S(O)2-NH-, R33-NH-S(O)2-NH-, R33-N(R33)-S(O)2-NH-, H2N-S(O)2-N(R71)-, R33-NH-S(O)2-N(R71)-, R33-N(R33)-S(O)2-N(R71)-, R33-C(O)-, HO-C(O)-, R33-O-C(O)-, H2N-C(O)-, R33-NH-C(O)-, R33-N(R33)-C(O)-, H2N-S(O)2-, R33-NH-S(O)2-, R33-N(R33)-S(O)2-, NC-, O2N- y oxo; R26, independientemente de cualquier otro grupo R26, se selecciona entre la serie que consiste en hidrogeno, fluor, alquilo C1-4 y HO-, o dos grupos R26 unidos al mismo átomo de carbono son oxo, o dos de los grupos R26 o un grupo R25 y un grupo R26, junto con los miembros de cadena comprendidos, forman un anillo monocíclico de 3 a 7 miembros que está saturado y contiene 0, 1 o 2 miembros de anillo hetero iguales o diferentes seleccionados de la serie que consiste en N, N(R34), O, S, S(O) y S(O)2, donde el anillo está opcionalmente sustituido en átomos de carbono del anillo por uno o más sustituyentes iguales o diferentes seleccionados de la serie que consiste en fluor y alquilo C1-4; R32 y R34 se eligen, independientemente entre sí, entre la serie que consiste en hidrogeno, R35, R35-S(O)2-, R35-C(O)-, R35-O-C(O)- y fenilo; R50 se selecciona entre la serie que consiste en R51-O- y R52-N(R53)-; R51 se selecciona entre la serie que consiste en hidrogeno y R54; R52 se selecciona entre la serie que consiste en hidrogeno, R55, NC- y R56-S(O)2-; R53 se selecciona entre la serie que consiste en hidrogeno y R57; R56 se selecciona entre la serie que consiste en R58 y fenilo; R60, independientemente de cualquier otro grupo R60, se selecciona entre la serie que consiste en hidrogeno y alquilo C1-4; R70 se elige entre la serie que consiste en HO-, R71-O-, R71-C(O)-O-, R71-S(O)m-, H2N-, R71-NH-, R71-N(R71)-, R71-C(O)-NH-, R71-C(O)-N(R71)-, R71-S(O)2-NH-, R71-S(O)2-N(R71)-, HO-C(O)-, R71-O-C(O)-, H2N-C(O)-, R71-NH-C(O)-, R71-N(R71)-C(O)-, H2N-S(O)2-, R71-NH-S(O)2-, R71-N(R71)-S(O)2- y oxo; R71, independientemente de cualquier otro grupo R71, se selecciona entre alquilo C1-4, cicloalquilo C3-4 y cicloalquil C3-4-alquilo C1-2-; Het1 es un anillo heterocíclico de 4 a 7 miembros monocíclico que comprende 1 o 2 miembros de anillo hetero iguales o diferentes seleccionados de la serie que consiste en N, N(R60), O, S, S(O) y S(O)2, donde el anillo está saturado y está opcionalmente sustituido con uno o más sustituyentes iguales o diferentes seleccionados de la serie que consiste en fluor y alquilo C1-4; m, independientemente de cualquier otro numero m, es un numero entero seleccionado de la serie que consiste en 0, 1 y 2; fenilo, independientemente de cualquier otro grupo fenilo, está opcionalmente sustituido con uno o más sustituyentes iguales o diferentes seleccionados de la serie que consiste en halogeno, alquilo C1-4, alquil C1-4-O- y NC-, a menos que se especifique lo contrario; cicloalquilo, independientemente de cualquier otro grupo cicloalquilo, e independientemente de cualquier otro sustituyente en el cicloalquilo, está opcionalmente sustituido con uno o más sustituyentes iguales o diferentes seleccionados de fluor y alquilo C1-4; alquilo, alquenilo y alquinilo, independientemente del grupo alquilo, alquenilo y alquinilo, e independientemente de cualquier otro sustituyente en alquilo, alquenilo y alquinilo, está opcionalmente sustituido con uno o más sustituyentes fluor; con la condicion de que el compuesto de la formula (1) no sea ácido 1-[(bifenil-4-carbonil)-amino]-ciclohexanocarboxílico, ácido 1-[4-(2-pirrolidin-1-il-etoxi)-benzoilamino]-ciclohexanocarboxílico, ácido 1-[4-(2-piperidin-1-il-etoxi)-benzoilamino]-ciclohexanocarboxílico, ácido 1-[4-(2-oxo-pirrolidin-1-il)-benzoilamino]-ciclohexanocarboxílico, ácido 1-{[4-(2-oxo-pirrolidin-1-il)-furan-2-carbonil]-amino}-ciclohexanocarboxílico, ácido 1-[(2',3-dicloro-bifenil-4-carbonil)-amino]-cicloheptanocarboxílico, éster metílico del ácido 1-[4-(4,6-dimetil-pirimidin-2-ilsulfanil)-benzoilamino]-ciclopentanocarboxílico, éster etílico del ácido 1-[4-(4-oxo-piperidin-1-iI)-benzoilamino]-ciclopropanocarboxílico o ácido 1-[2-cloro-4-(3-hidroxi- bencilcarbamoil)-benzoilamino]-ciclopropanocarboxílico. Reivindicacion 9: Un procedimiento para la preparacion de un compuesto de la formula (1) o una sal farmacéuticamente aceptable del mismo de acuerdo con una cualquiera o más de las reivindicaciones 1 a 8, que comprende hacer reaccionar un compuesto de la formula (3) con un compuesto de la formula (4), donde el anillo A y los grupos Y, Z, R20 a R22 y R50 en los compuestos de las formulas (3) y (4) se definen como en los compuestos de la formula (1) y pueden estar presentes grupos funcionales adicionales en forma protegida o en la forma de un grupo precursor, y el grupo G en el compuesto de la formula (4) es HO-, alquil C1-4-O- o halogeno. Reivindicaci
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09290831 | 2009-11-02 | ||
US31961910P | 2010-03-31 | 2010-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR079022A1 true AR079022A1 (es) | 2011-12-21 |
Family
ID=42040612
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100104007 AR079022A1 (es) | 2009-11-02 | 2010-10-29 | Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion |
Country Status (23)
Country | Link |
---|---|
US (2) | US8618304B2 (es) |
EP (1) | EP2496556B1 (es) |
JP (1) | JP5847088B2 (es) |
KR (1) | KR20120101429A (es) |
CN (1) | CN102858745A (es) |
AR (1) | AR079022A1 (es) |
AU (1) | AU2010313162A1 (es) |
BR (1) | BR112012010282A2 (es) |
CA (1) | CA2779268A1 (es) |
CO (1) | CO6541540A2 (es) |
CR (1) | CR20120203A (es) |
DO (1) | DOP2012000121A (es) |
EC (1) | ECSP12011861A (es) |
IL (1) | IL219354A0 (es) |
MA (1) | MA33772B1 (es) |
MX (1) | MX2012004739A (es) |
PE (1) | PE20121477A1 (es) |
RU (1) | RU2012122805A (es) |
TN (1) | TN2012000160A1 (es) |
TW (1) | TW201127379A (es) |
UY (1) | UY32990A (es) |
WO (1) | WO2011053948A1 (es) |
ZA (1) | ZA201202635B (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2012000435A (es) | 2009-07-08 | 2012-06-01 | Dermira Canada Inc | Analogos de acido 5-(tetradeciloxi)-2-furancarboxilico (tofa) utiles en el tratamiento de trastornos o afecciones dermatologicas. |
JP2014525932A (ja) | 2011-08-15 | 2014-10-02 | インターミューン, インコーポレイテッド | リゾホスファチド酸レセプターアンタゴニスト |
WO2013070879A1 (en) | 2011-11-10 | 2013-05-16 | Bristol-Myers Squibb Company | Methods for treating spinal cord injury with lpa receptor antagonists |
US9254288B2 (en) * | 2012-05-07 | 2016-02-09 | The Translational Genomics Research Institute | Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof |
CA2872213A1 (en) | 2012-06-13 | 2013-12-19 | F. Hoffmann-La Roche Ag | New diazaspirocycloalkane and azaspirocycloalkane |
AR092645A1 (es) | 2012-09-25 | 2015-04-29 | Hoffmann La Roche | Derivados biciclicos inhibidores de autotaxina (atx) |
US9169214B2 (en) | 2012-12-21 | 2015-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
UA118201C2 (uk) | 2013-11-26 | 2018-12-10 | Ф. Хоффманн-Ля Рош Аг | НОВИЙ ОКТАГІДРОЦИКЛОБУТА[1,2-c;3,4-c']ДИПІРОЛ-2-ІЛ |
EP3122750B1 (en) | 2014-03-26 | 2019-09-04 | F.Hoffmann-La Roche Ag | Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
MX2016010675A (es) | 2014-03-26 | 2016-11-10 | Hoffmann La Roche | Compuestos condensados de [1,4]diazepina como inhibidores de produccion de la autotaxina (atx) y acido lisofosfatidico (lpa). |
AU2015339089B2 (en) | 2014-10-30 | 2020-07-16 | Janssen Pharmaceutica Nv | Thiazoles as modulators of RORgammat |
PL3212642T3 (pl) | 2014-10-30 | 2020-04-30 | Janssen Pharmaceutica Nv | Tiazole podstawione amidami jako modulatory rorgammat |
JOP20200117A1 (ar) | 2014-10-30 | 2017-06-16 | Janssen Pharmaceutica Nv | كحولات ثلاثي فلوروميثيل كمُعدلات للمستقبل النووي جاما تي المرتبط بحمض الريتيونَويك ROR?t |
MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
US10118904B2 (en) | 2015-06-05 | 2018-11-06 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of Demyelinating Diseases |
MX2020004504A (es) | 2015-09-04 | 2021-11-10 | Hoffmann La Roche | Derivados de fenoximetilo. |
EP3353181B1 (en) | 2015-09-24 | 2021-08-11 | F. Hoffmann-La Roche AG | Bicyclic compounds as dual atx/ca inhibitors |
MX2018001890A (es) | 2015-09-24 | 2018-06-20 | Hoffmann La Roche | Compuestos biciclicos como inhibidores de autotaxina (atx). |
RU2018114289A (ru) | 2015-09-24 | 2019-10-24 | Ф. Хоффманн-Ля Рош Аг | Бициклические соединения в качестве ингибиторов аутотаксина (atx) |
BR112018006080A2 (pt) | 2015-09-24 | 2018-10-09 | F. Hoffmann-La Roche Ag | novos compostos bicíclicos como inibidores de dupla ação de atx/ca |
TW201803869A (zh) | 2016-04-27 | 2018-02-01 | 健生藥品公司 | 作為RORγT調節劑之6-胺基吡啶-3-基噻唑 |
WO2018106641A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles for the treatment of demyelinating diseases |
WO2018106646A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles for the treatment of demyelinating diseases |
WO2018106643A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
NZ755597A (en) | 2017-02-17 | 2023-06-30 | Eidos Therapeutics Inc | Processes for preparing ag-10, its intermediates, and salts thereof |
CR20190423A (es) | 2017-03-16 | 2019-11-01 | Hoffmann La Roche | Nuevos compuestos biciclícos como inhibidores dobles de atx/ca |
EP3596060B1 (en) | 2017-03-16 | 2023-09-20 | F. Hoffmann-La Roche AG | New bicyclic compounds as atx inhibitors |
US10961242B2 (en) | 2017-05-17 | 2021-03-30 | Legochem Biosciences, Inc. | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same |
KR101798840B1 (ko) | 2017-05-17 | 2017-11-17 | 주식회사 레고켐 바이오사이언스 | 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물 |
CN108276307A (zh) * | 2018-01-17 | 2018-07-13 | 常熟浸大科技有限公司 | 3-氰基-4-烃氧基苯甲酸酯的合成方法 |
WO2019183463A1 (en) | 2018-03-23 | 2019-09-26 | Eidos Therapeutics, Inc. | Methods of treating ttr amyloidosis using ag10 |
WO2019244002A1 (en) | 2018-06-18 | 2019-12-26 | Janssen Pharmaceutica Nv | Pyridinyl pyrazoles as modulators of roryt |
US11345666B2 (en) | 2018-06-18 | 2022-05-31 | Janssen Pharmaceutica Nv | Phenyl and pyridinyl substituted imidazoles as modulators of RORγT |
CN112292183A (zh) | 2018-06-18 | 2021-01-29 | 詹森药业有限公司 | 作为RORγt的调节剂的6-氨基吡啶-3-基吡唑 |
JP2021528405A (ja) | 2018-06-18 | 2021-10-21 | ヤンセン ファーマシューティカ エヌ.ベー. | RORγtのモジュレータとしてのアミド置換チアゾール |
US20200085810A1 (en) * | 2018-07-26 | 2020-03-19 | Hoffmann-La Roche Inc. | Compounds for use in treating kidney disorders |
MA53238A (fr) | 2018-08-17 | 2022-04-13 | Eidos Therapeutics Inc | Formules d'ag10 |
KR102224677B1 (ko) * | 2018-08-23 | 2021-03-08 | 가천대학교 산학협력단 | 티아졸로 피페라진 유도체 및 이를 유효성분으로 함유하는 자가면역질환 예방 또는 치료용 조성물 |
KR20220101137A (ko) | 2019-11-15 | 2022-07-19 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제로서의 트라이아졸 카르바메이트 피리딜 설폰아미드 및 이의 용도 |
CN111574389B (zh) * | 2020-05-14 | 2023-08-18 | 河北威远生物化工有限公司 | 1-氨基-4-取代环己基羧酸及其盐的顺式异构体的制备方法 |
TW202344504A (zh) | 2020-06-03 | 2023-11-16 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
WO2021247215A1 (en) | 2020-06-03 | 2021-12-09 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
WO2023107938A1 (en) | 2021-12-08 | 2023-06-15 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
TW202342017A (zh) | 2022-02-25 | 2023-11-01 | 美商洛子峰生物有限公司 | 用於治療與lpa受體活性相關的病狀的化合物及組合物 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5259644A (en) * | 1975-11-11 | 1977-05-17 | Sankyo Co Ltd | Stabilizer for polymer |
DE3602016A1 (de) | 1985-12-05 | 1987-06-11 | Bayer Ag | Pyri(mi)dyl-oxy- und thio-benzoesaeure-derivate |
DE69430747T2 (de) | 1993-07-28 | 2003-03-06 | Aventis Pharma Ltd | Verbindungen als pde iv und tnf inhibitoren |
KR20010082515A (ko) * | 1998-02-17 | 2001-08-30 | 우에노 도시오 | 아미디노 유도체 및 그 유도체를 유효 성분으로서함유하는 약제 |
HUP0101587A3 (en) | 1998-03-27 | 2003-03-28 | Genentech Inc | Antagonists for treatment of cd11/cd18 adhesion receptor mediated disorders |
PL350456A1 (en) * | 1999-03-15 | 2002-12-16 | Axys Pharmaceuticals | N−cyanomethylamides as protease inhibitors |
ATE420878T1 (de) | 2000-02-18 | 2009-01-15 | Kyowa Hakko Kirin Co Ltd | Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente |
DE10033353A1 (de) | 2000-07-08 | 2002-01-24 | Aventis Pharma Gmbh | Breit einsetzbares Verfahren zur Identifizierung von Modulatoren von G-Protein gekoppelten Rezeptoren |
US6525202B2 (en) | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
EP1361872A4 (en) | 2000-10-03 | 2004-05-19 | Univ Virginia | NOVEL LYSOPHOSPHATIDIC ACID RECEPTOR AGONISTS AND ANTAGONISTS |
JP2005519915A (ja) | 2002-01-18 | 2005-07-07 | セレテック・リミテッド・ライアビリティ・カンパニー | Edg受容体に関連する症状の処置方法 |
AU2003241833A1 (en) | 2002-05-28 | 2003-12-12 | Ono Pharmaceutical Co., Ltd. | Beta-ALANINE DERIVATIVE AND USE THEREOF |
KR100962972B1 (ko) * | 2002-07-26 | 2010-06-09 | 주식회사유한양행 | 1-페닐피페리딘-3-온 유도체 및 그의 제조방법 |
US20060122184A1 (en) | 2002-12-05 | 2006-06-08 | Axys Pharmaceuticals, Inc. | Cyanomethyl derivatives as cysteine protease inhibitors |
JP2006527200A (ja) | 2003-06-06 | 2006-11-30 | ファイブロゲン インコーポレイティッド | 窒素含有ヘテロアリール化合物および内因性エリトロポエチンを増加させる際のそれらの使用方法 |
CA2532800C (en) | 2003-07-23 | 2013-06-18 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
MXPA06002019A (es) | 2003-08-21 | 2006-05-31 | Osi Pharm Inc | Imidazopiridinas n3 sustituidas inhibidoras de c_kit. |
WO2005058790A1 (ja) | 2003-12-19 | 2005-06-30 | Ono Pharmaceutical Co., Ltd. | リゾホスファチジン酸受容体拮抗作用を有する化合物およびその用途 |
US7820703B2 (en) | 2004-05-06 | 2010-10-26 | University Of Virginia Patent Foundation | Lysophosphatidic acid receptor selective antagonists |
US7683097B2 (en) * | 2004-05-27 | 2010-03-23 | Propharmacon Inc. | Topoisomerase inhibitors |
GB2414403B (en) | 2004-05-28 | 2009-01-07 | Cilag Ag Int | Injection device |
MX2007004217A (es) * | 2004-10-15 | 2007-06-11 | Bayer Pharmaceuticals Corp | Preparacion y uso de derivados de acido bifenil-4-il-carbonilamino para el tratamiento de obesidad. |
EP1802606B1 (en) | 2004-10-19 | 2011-03-16 | Compass Pharmaceuticals LLC | Arylcarboxamides and their use as anti-tumor agents |
CN101098852A (zh) * | 2004-11-09 | 2008-01-02 | 史密丝克莱恩比彻姆公司 | 糖原磷酸化酶抑制剂化合物和其药物组合物 |
US20100130737A1 (en) | 2005-02-18 | 2010-05-27 | Takeda Pharmaceutical Company Limited | Regulating Agent of GPR34 Receptor Function |
WO2006128184A2 (en) | 2005-05-20 | 2006-11-30 | Alantos-Pharmaceuticals, Inc. | Pyrimidine or triazine fused bicyclic metalloprotease inhibitors |
ES2265276B1 (es) | 2005-05-20 | 2008-02-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
WO2007016538A2 (en) * | 2005-07-29 | 2007-02-08 | Bayer Healthcare Llc | Preparation and use of biphenyl amino acid derivatives for the treatment of obesity |
JP4047365B2 (ja) * | 2006-01-11 | 2008-02-13 | 生化学工業株式会社 | シクロアルカンカルボキサミド誘導体及びその製造方法 |
EP2040688B1 (en) * | 2006-06-28 | 2014-04-02 | Sanofi | New cxcr2 inhibitors |
FR2904827B1 (fr) * | 2006-08-11 | 2008-09-19 | Sanofi Aventis Sa | Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antiganistes des recepteurs a l'urotensine ii |
UA105178C2 (ru) | 2008-05-05 | 2014-04-25 | Санофи-Авентис | Ациламинозамещенные производные конденсированных циклопентанкарбоновых кислот и их применение как фармацевтических средств |
TW201010997A (en) * | 2008-06-18 | 2010-03-16 | Pfizer Ltd | Nicotinamide derivatives |
-
2010
- 2010-10-29 AR ARP100104007 patent/AR079022A1/es not_active Application Discontinuation
- 2010-11-01 UY UY32990A patent/UY32990A/es not_active Application Discontinuation
- 2010-11-01 TW TW99137400A patent/TW201127379A/zh unknown
- 2010-11-02 MX MX2012004739A patent/MX2012004739A/es not_active Application Discontinuation
- 2010-11-02 AU AU2010313162A patent/AU2010313162A1/en not_active Abandoned
- 2010-11-02 JP JP2012537183A patent/JP5847088B2/ja not_active Expired - Fee Related
- 2010-11-02 BR BR112012010282A patent/BR112012010282A2/pt not_active IP Right Cessation
- 2010-11-02 WO PCT/US2010/055035 patent/WO2011053948A1/en active Application Filing
- 2010-11-02 EP EP10776045.6A patent/EP2496556B1/en active Active
- 2010-11-02 CN CN2010800603352A patent/CN102858745A/zh active Pending
- 2010-11-02 CA CA2779268A patent/CA2779268A1/en not_active Abandoned
- 2010-11-02 PE PE2012000558A patent/PE20121477A1/es not_active Application Discontinuation
- 2010-11-02 RU RU2012122805/04A patent/RU2012122805A/ru not_active Application Discontinuation
- 2010-11-02 KR KR20127014323A patent/KR20120101429A/ko not_active Application Discontinuation
-
2012
- 2012-04-04 TN TNP2012000160A patent/TN2012000160A1/en unknown
- 2012-04-12 ZA ZA2012/02635A patent/ZA201202635B/en unknown
- 2012-04-22 IL IL219354A patent/IL219354A0/en unknown
- 2012-04-25 CR CR20120203A patent/CR20120203A/es unknown
- 2012-04-26 DO DO2012000121A patent/DOP2012000121A/es unknown
- 2012-04-30 EC ECSP12011861 patent/ECSP12011861A/es unknown
- 2012-05-01 US US13/461,264 patent/US8618304B2/en not_active Expired - Fee Related
- 2012-05-02 CO CO12071019A patent/CO6541540A2/es unknown
- 2012-05-30 MA MA34905A patent/MA33772B1/fr unknown
-
2013
- 2013-11-27 US US14/091,511 patent/US9018383B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU2010313162A1 (en) | 2012-05-24 |
TN2012000160A1 (en) | 2013-12-12 |
ECSP12011861A (es) | 2012-10-30 |
JP5847088B2 (ja) | 2016-01-20 |
US8618304B2 (en) | 2013-12-31 |
RU2012122805A (ru) | 2013-12-10 |
CR20120203A (es) | 2012-06-01 |
BR112012010282A2 (pt) | 2016-03-29 |
DOP2012000121A (es) | 2012-07-31 |
US20120264790A1 (en) | 2012-10-18 |
EP2496556A1 (en) | 2012-09-12 |
MA33772B1 (fr) | 2012-11-01 |
TW201127379A (en) | 2011-08-16 |
ZA201202635B (en) | 2013-01-30 |
CA2779268A1 (en) | 2011-05-05 |
CN102858745A (zh) | 2013-01-02 |
CO6541540A2 (es) | 2012-10-16 |
JP2013509446A (ja) | 2013-03-14 |
UY32990A (es) | 2011-05-31 |
PE20121477A1 (es) | 2012-11-14 |
MX2012004739A (es) | 2012-05-22 |
US9018383B2 (en) | 2015-04-28 |
US20140088158A1 (en) | 2014-03-27 |
WO2011053948A1 (en) | 2011-05-05 |
EP2496556B1 (en) | 2018-12-26 |
KR20120101429A (ko) | 2012-09-13 |
IL219354A0 (en) | 2012-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR079022A1 (es) | Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion | |
AR074622A1 (es) | Derivados de acido ciclopentanocarboxilico condensados sustituidos con acilamino y su uso como productos farmaceuticos | |
ECSP066829A (es) | 5,6 dialquil-7 -amino-triazolopirimidinas, procedimientos para su preparacion y el uso de las mismas para combatir hongos nocivos | |
ECSP10010405A (es) | Procesos e intermediarios para la preparacion de derivados de acido 5-bifenil-4-il-2-metilpentanoico | |
ECSP14020586A (es) | Composición para el control de plagas que incluye un derivado de iminopiridina novedoso | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
UY32490A (es) | Inhibidores de beta-secretasa | |
AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
AR064389A1 (es) | Derivados heterociclicos de nicotinamida utiles en el tratamiento de afecciones y enfermedades alergicas y respiratorias, y composiciones farmaceuticas que los contienen. | |
AR075583A1 (es) | Derivados de isoxazol/o-piridina con eslabon etilo o etenilo | |
CU20110216A7 (es) | Derivados aminobutíricos sustituidos como inhibidores de neprilisina | |
AR065464A1 (es) | Derivados de nicotinamida. composiciones farmaceuticas | |
AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
PE20151666A1 (es) | Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep | |
EA200801828A2 (ru) | Соединения 1,2,4,5-тетрагидро-3h-бензазепина, способ их получения и фармацевтические композиции, содержащие эти соединения | |
UY33337A (es) | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS | |
CY1114689T1 (el) | C7-φθορο υποκατεστημενες ενωσεις τετρακυκλινης | |
CO6561828A2 (es) | Derivados de imidazol como inhibidores de proteina de huso de cinesina (eg-5) | |
AR066972A1 (es) | Derivados azapeptidicos | |
AR086086A1 (es) | Derivados glucosidos y usos de los mismos | |
AR085014A1 (es) | Derivados de acido 3-heteroaroilamino-propionico amino-sustituidos y su uso como composiciones farmaceuticas | |
ECSP13012838A (es) | Nuevos compuestos de benzodioxol-piperazina | |
CL2022002975A1 (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso | |
AR075737A1 (es) | SALES DE ADICIoN DE TROMETAMINA CON DERIVADOS DE ACIDO AZABIFENILAMINOBENZOICO COMO INHIBIDORES DE DHODH Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENE | |
AR071538A1 (es) | Derivados de macrolactona |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |